NervGen Pharma Corp.
NGENHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeNervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma. Valued at $212.4M, NGEN is a micro-cap name in its sector. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Market Cap
$212.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.27
EPS (TTM)
$-0.46
EPS (Fwd)
$-0.38
ROE
-1207.5%
ROA
-90.8%
Cash
$16.6M
Total Debt
$0
Free CF
-$13.2M
52W Change
-15.6%
Annual Financials
Cash vs Debt
NervGen Pharma Corp. reports $16.6M in cash and $0 in total debt. Free cash flow is running at -$13.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -1207.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NervGen Pharma Corp.'s trajectory.